Pooled data analyses revealed that tadalafil 5 mg once daily allows the clinical ly-meaningful improvement of LUTS and nocturnal voiding frequency independent of both erectile dysfunction severity and improvement .
PDE5-Is are safe and effective in improving both LUTS and erectile function in appropriately selected men with LUTS/BPE .
We found evidence to confirm that phosphodiesterase type 5 inhibitors are a valid treatment option for men affected by bothersome urinary symptoms with or without erectile dysfunction
CONTEXT Several pre clinical reports , r and omized controlled trials , systematic review s , and posthoc analyses corroborate the role of phosphodiesterase type 5 inhibitors ( PDE5-Is ) in the treatment of men with lower urinary tract symptoms ( LUTS ) associated with benign prostatic enlargement ( BPE ) .
OBJECTIVE Up date of the latest evidence on the mechanisms of action , evaluate the current meta-analyses , and emphasize the results of pooled data analyses of PDE5-Is in LUTS/BPE .
PATIENT SUMMARY We review ed recent literature on phosphodiesterase type 5 inhibitors in men with lower urinary tract symptoms associated with prostatic enlargement .
Tadalafil once daily improves ejaculatory function, erectile function, and sexual satisfaction in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia and erectile dysfunction: results from a randomized, placebo- and tamsulosin-controlled, 12-week double-blind study.
INTRODUCTION Tadalafil , a long-acting phosphodiesterase type 5 inhibitor , is approved for treating signs and symptoms of benign prostatic hyperplasia ( BPH ) and erectile dysfunction ( ED ) ; tamsulosin , an alpha-blocker , is approved for treating signs and symptoms of BPH . AIM To determine the effects of tadalafil or tamsulosin on sexual function , including ejaculation and orgasm , satisfaction , and erectile function , in sexually active men with ED and lower urinary tract symptoms suggestive of BPH ( LUTS/BPH ) . METHODS A r and omized , double-blind , placebo-controlled study of tadalafil 5 mg once daily for 12 weeks in men with LUTS/BPH ; tamsulosin 0.4 mg once daily was an active control . MAIN OUTCOME MEASURES The International Index of Erectile Function ( IIEF ) question naire was administered at baseline and 4 , 8 , and 12 weeks . Analysis of orgasm and ejaculation was post hoc based on the IIEF-Orgasmic Function ( OF ) domain ( IIEF-Q9 [ ejaculatory frequency ] and Q10 [ orgasmic frequency ] ) . Other measures included IIEF-Intercourse Satisfaction ( IS ) , Overall Satisfaction ( OS ) , and Erectile Function ( EF ) domains . Changes from baseline to 12 weeks ( or last observation ) vs. placebo were analyzed using analysis of covariance . Higher IIEF scores indicate better functioning . RESULTS Of 511 study participants , 310 ( 60.7 % ) had ED and were sexually active . The IIEF-OF increased significantly through 12 weeks with tadalafil vs. placebo ( P = 0.048 ) , as did IIEF-Q9 ( P = 0.045 ) but not IIEF-Q10 ( P = 0.100 ) . Compared with placebo , IIEF-OF , Q9 , and Q10 decreased significantly with tamsulosin ( all P < 0.05 ) . The IIEF-IS and OS increased significantly at end point with tadalafil ( both P < 0.001 ) ; for tamsulosin , change was not significant for IS , while OS decreased significantly ( P = 0.009 ) . The IIEF-EF domain increased significantly vs. placebo with tadalafil ( P < 0.001 ) but not tamsulosin ( P = 0.699 ) . CONCLUSIONS Tadalafil 5 mg once daily significantly improved ejaculation and orgasm , intercourse and overall satisfaction , and erectile function . Men receiving tamsulosin 0.4 mg once daily experienced a decrease in both ejaculatory/orgasmic frequency and overall satisfaction vs. placebo , with no significant effect on erectile function
Pooled data analyses revealed that tadalafil 5 mg once daily allows the clinical ly-meaningful improvement of LUTS and nocturnal voiding frequency independent of both erectile dysfunction severity and improvement .
PDE5-Is are safe and effective in improving both LUTS and erectile function in appropriately selected men with LUTS/BPE .
We found evidence to confirm that phosphodiesterase type 5 inhibitors are a valid treatment option for men affected by bothersome urinary symptoms with or without erectile dysfunction
CONTEXT Several pre clinical reports , r and omized controlled trials , systematic review s , and posthoc analyses corroborate the role of phosphodiesterase type 5 inhibitors ( PDE5-Is ) in the treatment of men with lower urinary tract symptoms ( LUTS ) associated with benign prostatic enlargement ( BPE ) .
OBJECTIVE Up date of the latest evidence on the mechanisms of action , evaluate the current meta-analyses , and emphasize the results of pooled data analyses of PDE5-Is in LUTS/BPE .
PATIENT SUMMARY We review ed recent literature on phosphodiesterase type 5 inhibitors in men with lower urinary tract symptoms associated with prostatic enlargement .